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Summary Small cell carcinoma (SCC) is considered to be of neuroendocrine origin. Neurone specific enolase
(NSE) and PGP 9.5 are markers of neural and neuroendocrine differentiation. S-100 protein is a marker of
glial differentiation. The expression of these markers in endobronchial biopsy and lung tumour resection
specimens was studied to see if any diagnostic, prognostic or therapeutic implications would emerge.
Zamboni fixed endobronchial tumour biopsy specimens from 20 patients were examined. Twelve of these
were cases of SCC and 8 were non-SCC. Of the 12 SCC, 7 were positive for NSE, 6 for PGP9.5 and 5 for S-
100 protein. Cases which showed a positive reaction for NSE had a mean survival of 9.1 months compared
with 3.9 months for those with a negative reaction, but the number of cases is too small to assign any
statistical significance. There was no difference in survival times between positive and negative reactors for
PGP 9.5 and S-100 protein. All 8 cases of non-SCC showed positive reactions to all three markers.
Of 32 formalin fixed lung tumour resection specimens 6 were cases of SCC, 25 non-SCC and a
chemodectoma. Three of the 6 cases of SCC showed positive staining for NSE, 3 for PGP9.5 and 1 for S-100
protein. Of the 25 non-SCC, 10 were positive for NSE, 12 for PGP9.5 ard 6 for S-100 protein. The 1
chemodectoma stained positively for all tihree markers.
Neuroendocrine markers are of little value in differentiating SCC from non-SCC. Positive staining for NSE
in SCC may be an indicator of prolonged survival but further investigation is required.
The management of lung carcinoma is determined
by histological type often based solely upon results
of bronchoscopic lung biopsies. A surgical
approach constitutes primary treatment for
operable cases of squamous carcinoma, adeno-
carcinoma and carcinoid while such therapy for
small cell carcinoma shows poor results (Weiss,
1978; Miller et al., 1969) and therefore radiation
and chemotherapy are recommended. Results of
these forms of treatment remain poor and median
survival, at best, is 11 months (Spiro, 1982).
Small cell carcinoma is considered to be a neuro-
endocrine type tumour (Bensch et al., 1968; Gould
et al., 1983; Carter, 1983). Neurone specific enolase
(NSE) and PGP 9.5 are markers of neural and
neuroendocrine differentiation (Schmechel et al.,
1978; Thompson et al., 1983). S-100 protein is a
marker of glial differentiation as well as beipg
found in melanomas, Langerhans cells and cartila-
genous tumours (Weiss et al., 1983). We studied the
expression of these neural markers in lung biopsy
specimens to see if any diagnostic, prognostic or
therapeutic implications would emerge, since
morphologic assessment alone is inadequate
(Strauchen et al., 1983).
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In addition, a range of resected lung carcinomas
were studied to provide a framework for inter-
pretation of immunostaining of the lung biopsies.
Materials and methods
Tissue specimens
The biopsy study was performed prospectively.
Endobronchial biopsies from 20 patients (Table I)
were taken as part of the usual assessment of those
with lung carcinoma. The tissue was immediately
fixed in Zamboni fixative (Schmechel et al., 1980) -
a buffered paraformaldehyde, glutaraldehyde and
picric acid mixture. Routine paraffin embedding
was employed and sections were cut at 5gm. One
section of each case was stained with haematoxylin
and eosin.
An indirect immunoperoxidase technique was
applied for the demonstration of NSE, PGP9.5 and
S-100 protein. Endogenous peroxidase was
quenched with 3% hydrogen peroxide for 15min
and each of the primary antisera was used at a
dilution of 1/100 for 30min. Swine anti-rabbit
globulin conjugated to peroxidase (Dako) was used
at 1/50 dilution for 30min and immunolocalisation
was demonstrated with diaminobenzidine with
hydrogen peroxide.
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Table I Clinical data and immunohistochemistry of bronchoscopic
specimens.
Stage Treatment Response Survival NSE PGP S-100
sCC
i 1 L C CR >13mo + + +
o 2 L C+D CR 18 mo + + +
o 3 L C PR 10mo + - -
o 4 E C PR >l5mo + - -
0 5 E C PR 10MO - - -
0 6 E C PR 4mo - - +
i 7 E C PR 1l mo + +
0 8 E C PR 11mo - +
0 9 E C Lost to follow up - - -
o 10 E NT 6mo + + +
i11 E NT 1mo + + +
o 12 E NT Imo
NON SCC
1 L S Died post op + + +
2 L D - Imo + + +
3 E NT - >6mo + + +
4 L NT - >8mo + + +
5 E NT - >11mo + + +
6 E NT - 6mo + + +
7 E NT - 1mo + + +
8 L S - >lOmo + + +
KEY: i =small cell carcinoma, intermediate type; o =small cell
carcinoma, oat cell type; L=disease limited to hemithorax (limited);
E=disease beyond heimthorax (extensive); C=chemotherapy;
D=radiotherapy; S=surgery (pneumonectomy or lobectomy);
CR=complete response to chemotherapy as judged by clearing of
visible tumour clinically, radiologically and bronchoscopically;
PR=partial response to treatment, reduction of tumour but not
complete response.
Rabbit anti-NSE and anti-PGP 9.5 were prepared
and characterised as described previously (Hullin et
al., 1980; Dhillon et al., 1982; Thompson et al.,
1983; Doran et al., 1983; Rode et al., 1985). These
studies confirmed the specificity of these markers.
No staining for NSE and PGP 9.5 of normal non-
neural or non-neuroendocrine tissues was observed.
The small quantities of NSE and PGP9.5 found in
extracts of tissues usually not regarded as neuro-
endocrine or neural can be explained by the
presence in these tissues of nerves and cell
populations representing the diffuse neuroendocrine
system. Rabbit anti- S-100 protein was a generous
gift from Dako. Negative controls were performed
using non-immune serum in place of the specific
primary antibody. Absorption studies were not
performed. Positive controls comprised a section of
nerve which was included with each batch of
sections of lung biopsy being immunostained.
Each biopsy was assessed histologically. Immuno-
staining was assessed initially on a scale of none,
slight, moderate and strong staining. Those cases
showing none and slight staining only were assigned
to a negative category and those showing moderate
and strong staining were assigned to a positive
category.
The study of lungs resected for carcinoma
consisted of sections taken from formalin fixed
paraffin processed material taken from the files of
the Bland-Sutton Institute of Pathology. Represen-
tative sections were cut at 5gm and stained (as
above) from 6 cases of squamous cell carcinoma
(1 well, 3 moderately and 2 poorly differentiated),
7 cases of adenocarcinoma (2 moderately, 4
poorly differentiated and 1 broncho-alveolar cell
carcinoma), 8 carcinoid tumours, 3 large cell
carcinomas, 6 small cell carcinomas (3 intermediate
and 3 oat cell), 1 adenoid cystic carcinoma and
1 chemodectoma (Table II). Metastasis to the
lung from other sites was excluded by pre-operative
clinical assessment.
Clinical assessment
Clinical assessment included physical examination,
radiology, biochemistry, fibreoptic bronchoscopy,NEURAL MARKERS IN LUNG CANCER 647
iliac crest marrow aspiration and isotope bone
scan. Disease extent was judged as being limited
or extensive. Limited disease was that confined to
one hemithorax (including the ipsilateral supra-
clavicular fossa) and extensive was outside these
limits (Spiro, 1983).
Nine of the 12 patients with small cell carcinoma
received specific chemotherapy. This consisted of
between 1 and 8 courses of cyclophosphamide,
vincristine and VP 16. The bronchoscopy specimen
from patient 7 was obtained at relapse following 8
courses of chemotherapy - this patient subsequently
received radiotherapy to the primary thoracic site
of relapse. Response to chemotherapy was judged
to be complete (CR) if there was clearing of visible
tumour clinically, radiologically and broncho-
scopically; partial response (PR) was anything less
than this.
Two of the 8 non-small cell cases underwent
surgical resection of the limited tumour. One
patient received palliative radiotherapy.
Results
Immunohistochemistry
Of the 20 endobronchial biopsy specimens there
were 12 cases of small cell carcinoma (9 oat cell
and 3 intermediate). Two cases of undifferentiated
large cell carcinoma, 4 cases of poorly differentiated
squamous, 1 moderately differentiated squamous
and 1 well differentiated squamous cell carcinoma
were represented. The predominance of oat cell
tumours in this study reflects the referral of patients
with this type of tumour from other centres to one
of the authors (S.G.S.) for treatment.
Four small cell carcinomas (2 intermediate, 2 oat
cell) (Figures 1-3) and all large cell anaplastic and
squamous cell carcinomas (Figures 4-8) stained for
NSE, PGP9.5 and S-100 protein. One small cell
carcinoma (intermediate) stained for NSE and
PGP9.5. Four oat cell carcinomas stained for one
marker only (2 for NSE, 1 for PGP 9.5 and 1 for S-
100 protein). Three oat cell carcinomas did not
stain for any of the markers. No staining was seen
in the companion sections where non immune
serum was substituted for primary antibody.
Staining of scattered bronchial epithelial, mucous
gland and cartilage cells for each of the markers
was seen in occasional biopsies.
In the resection specimens, of 6 squamous
carcinomas 4 showed staining for NSE, 3 for
PGP9.5 and 4 for S-100 protein. Of 3 large cell
anaplastic carcinomas staining for NSE was present
in 1, for PGP9.5 in 2 and none showed staining for
S-100 protein. Six small cell carcinomas were
studied, 3 oat and 3 intermediate cell types. Two
intermediate type cancers stained for NSE and
PGP9.5, none stained for S-100 protein. Staining
of oat cell carcinoma was seen in one case only that
was positive for NSE, PGP9.5 and S-100 protein.
No staining for NSE and S100 protein was seen in
adenocarcinomas. Two (moderately differentiated)
of the 7 adenocarcinomas stained for PGP9.5. Of
the 8 carcinoid tumours, 5 stained for NSE, 5 for
PGP9.5 and 2 for S-100 protein. The 1 chemodec-
toma represented in the study stained for all 3
markers employed whilst 1 adenoid cystic
carcinoma was negative for the 3 antigens.
These results are summarised in the Tables 1 and 2.
Clinical correlates
Small cell carcinoma Three of the 12 patients had
limited disease and all three received chemotherapy.
Two of these 3 showed a complete response and the
mean survival of these 3 was 14 months. The 2
complete responders were positive for NSE,
PGP9.5 and S-100 protein; the partial responder
was positive only for NSE.
Six of the 9 "extensive" group also received
chemotherapy but 1 was lost to follow-up. The
remaining 5 showed a partial response to treatment
only and their mean survival was 6 months. Two of
these 5 were positive for NSE, two for PGP 9.5 and
only 1 for S-100 protein.
Three of 12 patients were not treated. Two of
these 3 were positive for NSE, PGP9.5 and S-100
protein; one survived 6 months and the other 2
weeks. The third case was negative for all three
markers and survived one week only.
Cases which demonstrated a positive reaction for
NSE had a mean survival of 9.1 +7 months (n=7);
those with a negative reaction survived 3.9+4
months (n=4). The number of cases is too small to
assign any statistical significance.
Comparing positive and negative responders to
PGP 9.5 and S-100 protein showed no differences in
survival.
Non-small cell carcinoma All 8 cases were positive
for all 3 neuroendocrine markers. Survival ranged
from 1 week to >11 months in these patients.
Discussion
The histogenesis of carcinomas of lung is the
subject of current debate. Most tumours can be
assigned to a category such as squamous, small cell,
adeno or large cell carcinoma on the predominant
morphological features. However, with adequate
sampling it is recognised that many tumours
express a combination of these appearances not
only in different parts of the tumour (Willis, 1948)
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Figure 6 Moderately differentiated squamous cell
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Table II Immunohistochemical results of lung tumour resection specimens.
NSE PGP S-100 NSE PGP S-100
Small cell carcinoma 1 + + - Squamous carcinoma 1 + - +
intermediate 12 + + - 2 + + +
3 - - _ 3 + - +
(4 - 4 - + -
oat 5 - - - 5
6 + + + 6 + + +
Large cell carcinoma 1 - - - Adenocarcinoma 1 - +
2 + + - 2 - + -
3 - + 3 - _ _
Carcinoid 1 - - - 4
2 + _ 5 - _
3 - _ 6 - _ _
4 + + 7 - _ _
5 - + - Adenoid Cystic
6 + + + carcinoma 1
7 + + - Chemodectoma 1 + + +
8 + + +
but within the same tumour cells (McDowell &
Trump, 1981). Gusterson (1984) found keratin-like
immunoreactivity expressed in a range of lung
tumours. Based on these findings and a review of
the literature he concluded that there is only one
entity, bronchial carcinoma. In particular neural
characteristics such as expression of NSE (in serum
or immunohistochemically), L-dopa decarboxylase
and neurosecretory granules are seen not only in
small cell carcinoma but in carcinomas appearing
to be large cell anaplastic, squamous or adeno-
carcinoma by light microscopy (Sidhu, 1980;
McDowell et al., 1981; Dhillon et al., 1982; Baylin
et al., 1982). A combination of types we have
personally observed on several occasions is the
association of squamous and small cell carcinoma.
On a theoretical level variability in staining can
be explained by epigenetic or genetic differences
between cells of the same tumour. Inconstant
expression of genes in different parts of a tumour
may result in heterogenous phenotypes. This may
be due to spontaneous mutation of tumour cells or,
alternatively, it is possible that tumours have a
pleoclonal origin, contrary to the usual dogma of
monoclonal derivation of cancer (Woodruff, 1983).
Whatever the explanation it is clear that tumour
heterogeneity is the rule rather than the exception.
On a pragmatic level the implications are worrying
because it would be difficult to design therapy for a
tumour composed of a mixture of cell types and the
radically divergent, possibly inappropriate manage-
ments that may be determined by the small sample
represented in a lung biopsy.
We undertook this study to determine whether
staining of lung biopsies for neural markers has any
practical connotations for diagnosis, prognosis or
therapy. Zamboni fixation (Schmechel et al., 1980)
was chosen because previous work with formalin
fixed biopsies (Rode et al., 1984) had shown this to
be unsatisfactory.
Undifferentiated large cell and squamous car-
cinoma expressed NSE, PGP9.5 and S-100 protein
consistently, while a proportion only of small
cell tumours showed staining. In a recent study
Sheppard and co-workers (1984) found NSE
immunoreactivity in 18/31 (58%) of small cell
carcinomas examined. These figures compare
favourably with our findings where 7/12 (58%) of
bronchoscopic SCC specimens and 3/6 (50%) SCC
resection specimens were positive for NSE. Using a
different antibody, fixation and method from the
one employed in the present study these authors
were unable to demonstrate NSE in non-SCC
though radioimmunoassay performed on 3 cases of
non-SCC showed the presence of this protein, albeit
in lower concentrations than the 2 cases of SCC
examined. Small cell carcinoma is supposed to be
the major neuroendocrine tumour of this group
(Bensch et al., 1968) and the results are intriguing
since they are the opposite of what was expected.
One possible reason is that small tumour cells are
more fragile and are prone to crush injury,
perhaps with a loss of the antigens in question. It
has been observed in experimentally induced
neoplasms of hamsters (Gould & Linnoila, 1982)
that small proliferations of "neuroendocrineNEURAL MARKERS IN LUNG CANCER 651
bodies" initially composed of small cells become
more squamoid as well as expressing other
phenotypes as these tumours enlarge and grow.
Thus it may be that large cell anaplastic and
squamous carcinoma are expressing a true neural
lineage, and having more cytoplasm show more
staining for predominantly cytoplasmic neural
antigens such as NSE, PGP9.5 and S-100 protein.
Conversely, there are instances of expression of
characteristics inappropriate to the supposed origin
of tumours and this may be another example. This
atypia can be morphological i.e. "metaplastic"
changes such as rhabdomyosarcomatous or
glandular differentiation in nerve sheath tumours
(Woodruff et al., 1973; Woodruff, 1976) or
functional i.e. the many instances of ectopic
hormone production (Rees & Ratcliffe, 1974). Of
particular interest in this regard is the
"inappropriate" expression of NSE by chemically
induced gliomas in rats (Vinores et al., 1984) with
the interesting speculation that the tumour cells
evolve expression of NSE because it is a
particularly stable form of the enzyme, resistant to
a hypothetically adverse tumour microenvironment.
The staining patterns seen in the formalin fixed
material of surgically resected lung tumours are
similar to the findings of the lung biopsy series. The
formalin fixed tumours show less staining in each
tumour category. This is explained by suboptimal
fixation of the material by formalin.
Despite this consideration, it would appear that
as a diagnostic adjunct for the designation of small
cell carcinoma, staining for NSE, PGP9.5 and S-
100 protein has no value, even in optimally fixed
biopsies.
Often it is optimistically asserted that accurate
histogenetically orientated diagnosis of cancer will
assist in determining rational therapy and
evaluating prognosis (Neville et al., 1978; Gould et
al., 1983), but this study suggests that this is not
the case. Perhaps, if environment is the prime
determinant of tumour expression, systemic therapy
designed on a site selective basis might be more
logical and efficacious than current rationale based
on presumed histogenetic specificity. Positive
staining for neuroendocrine markers did not help in
distinguishing between oat and non-oat cell types of
carcinoma. Indeed, our results suggest that if such
staining is performed and expression of these
markers is seen, the possibility of large cell
anaplastic, squamous or carcinoid tumour should
be reconsidered. In keeping with this the survival of
patients with oat cell carcinoma whose tumours
demonstrate a positive reaction to NSE does
appear to be slightly longer than those who show a
negative reaction, whether they have, received
chemotherapy or not. But this difference is not
significant and further work is needed in this
context.
In conclusion, the diagnosis of small cell
carcinoma of lung in endobronchial biopsy
specimens has profound consequences in the
management of these patients. Morphological
difficulties in diagnosis lie between malignant or
atypical carcinoid and small cell carcinoma on the
one hand and small cell carcinoma (intermediate
type) and anaplastic large cell or squamous cell
carcinoma on the other. Such distinctions may be
artificial and combinations of these morphological
types occur.
Staining for NSE, PGP9.5 and S-100 protein is
of little value in the positive identification of small
cell carcinoma of lung by endobronchial biopsy.
The slightly longer survival of oat cell cases
showing positive reactions for NSE suggests that
this avenue of research as a prognostic indicator
may be worth pursuing.
We wish to thank Prof. N. Woolf for generous help and
encouragement.
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